Gilead’s Livdelzi meets ALP normalization endpoint in 75.4% of patients in Phase 3 PBC trial
GILD•Gilead Sciences said Livdelzi normalized alkaline phosphatase in 75.4% of patients in its Phase 3 IDEAL trial for primary biliary cholangitis. No new safety concerns emerged, and Gilead is discussing the results with global regulators.
1. Phase 3 results
Gilead Sciences reported that Livdelzi met the alkaline phosphatase normalization endpoint in 75.4% of patients in the Phase 3 IDEAL trial, which evaluated second-line treatment for primary biliary cholangitis in patients with mildly elevated levels of the liver marker. No new safety concerns emerged, and adverse event rates were generally similar between treatment groups.
2. Next steps
Gilead is discussing the results with global regulators. The results are scheduled for presentation at The Liver Meeting in Denver on November 5-9, 2026, and publication has been accepted by the Journal of Hepatology.
